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The recent ten to twenty years have seen a substantial progress in the diagnosis and treat-
ment  of breast cancer. A rapid development of various curative options has led to the
improvement of treatment outcomes, while paying more and more attention to the aspects
of  quality of life and cosmetic effect. In our publication, we wish to outline certain trends
in  the development of modern treatment of breast cancer. Among topics discussed are new
forms of molecular diagnostics, new approach to the idea of sentinel node biopsy, as wellentinel node biopsy
eoadjuvant treatment
ntraoperative radiotherapy
as  new techniques for delivery of medical procedures, the increasing use of nomograms,
progress in the techniques of breast conservative treatment, modern approach to occult
breast lesions, the increasing use of neoadjuvant treatment and intraoperative radiotherapy.
and C
breast.©  2013 Greater Pol
.  Introduction
n Poland, over 14,000 women are diagnosed with breast
ancer (BC) each year (48/100,000), with mortality of 5000
14.5/100,000). The incidence of BC increases with age reaching
ts peak at 50–59 years (approximately 32% of all cases). The
isease occurs particularly in post-menopausal women (78%),
ith only 22% of patients below 50 years of age. BC below
5 years occurs rarely, representing just 3% of all cases, and
xceptionally in women below 25 years.1–5
Notably, the breast cancer mortality rate in Poland shows
 declining trend, which may indicate an improvement in BC
iagnosis and treatment methods (0.64 in 1963, 0.38 in 2005).1,6
he novelties in BC diagnosis and treatment are presented in
his report.
The last decades have witnessed profound transforma-
ions in BC therapy. The prognosis has improved considerably
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and patient’s quality of life has become a matter of concern
for both medical professionals involved in the diagnostic and
therapeutic process and scientists developing new approaches
and treatment modalities which determine progress in this
area. Only a few decades ago, women with diagnosed BC were
treated with radical mastectomy including axillary lymph
node dissection (ALND) to achieve a proper locoregional con-
trol and enable full recovery. While this treatment goal has
remained valid up to the date, the surgical approach has come
to be more  conserving and selective both with regard to the
breast and axillary lymph nodes. The impact of surgery on
patient’s quality of life is manifested with less mutilating pro-
cedures or the application of novel techniques which allow to
deliver satisfactory cosmetic effect on the appearance of thet I, Greater Poland Cancer Centre, Poznan´, Poland.
It is now believed that patients with diagnosed BC should
be referred to specialised breast units which are able to ensure
diagnosis and therapy adequate for that disease. Decisions
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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regarding individual treatment are from the very beginning
taken by a multidisciplinary team composed of a surgeon,
clinical oncologist, radiation therapist, psychologist, physical
therapist, nurse, and social worker. Such a system makes it
possible to plan an optimal treatment being a resultant of
available treatment methods for each stage of the disease,
patient’s expectations, logistics, costs, as well as possible com-
plications and distant treatment outcomes.
It is estimated that around 30–50% of patients referred
to breast units have their treatment plans changed
after re-assessment of their examination results, mainly
regarding surgery, but also the interpretation of imaging and
histopathology test results,7 hence a signiﬁcant need for such
units to be established.
The European Society of Breast Cancer Specialists
(EUSOMA) has deﬁned a set of criteria to be met  by a breast unit
and conditions of eligibility for accreditation and European
Cancer Care Certiﬁcation. They are aimed to raise the qual-
ity of diagnosis, treatment and care of breast cancer patients
across Europe. Soon, as it seems, each diagnosis of breast can-
cer will lead to patient being referred to a specialised breast
unit.
2.  Fundamental  science
Recently, apart from the standard determination of can-
cer stage according to the TNM classiﬁcation, expression of
oestrogen and progesterone receptors and HER2 receptor, the
genetic proﬁle of cancer has increasingly been determined.8–12
The molecular proﬁle of a tumour helps in taking therapeutic
decisions and establishing more  precise prognosis of oncology
patients. There are several tests available at the moment. The
ﬁrst of them, a 21-gene recurrence score assay Oncotype DX®.
The result, referred to as recurrence score (RS) evaluates the
response to hormonal therapy and chemotherapy in oestrogen
positive BC. Another commercially available test is a 70-gene
MammaPrint assay.13 That test allows to evaluate the risk of
distant metastases in patients with early BC. Tests are per-
formed on a fresh tissue collected from the tumour by biopsy
or during surgery.
Yet another test to help differentiate BC subtypes is the
division proposed by Perou into the following subgroups:
luminal A, luminal B, basal, HER-2 over-expressing, and
normal-like.14 The basal type of BC is the one with negative
oestrogen and progesterone receptors, and HER2 protein. This
excludes hormonal and trastuzumab-based treatment. The
division helps in determining the response to chemotherapy
and evaluating prognosis. Soon, owing to the molecular can-
cer evaluation, treatment personalisation will become a basic
tool to identify treatment method and patient prognosis.
3.  Sentinel  node  biopsy
The publication of the report by Veronesi et al. marked the
beginning of a new approach to surgical treatment of BC where
efforts are made to limit the extent of procedure as much as
possible.15 However, the removal of the axillary lymph system
remains an integral part of treatment. Why ALND? First, it is
important to remove cancerous tissue, that is metastasis, iniotherapy 1 9 ( 2 0 1 4 ) 165–172
axillary lymph nodes. It has been proved that lymphadenec-
tomy in that group of patients reduces the number of relapses
and has a favourable impact on long-term survival. Second,
and very importantly, pathology results of dissected lymph
nodes provide full information on the stage of disease. It is a
main factor determining the inclusion and extent of adjuvant
treatment.
For all the above beneﬁts, lymphadenectomy also involves
a number of complications, the most common of them includ-
ing: lymphatic oedema of the upper limb, movement  and
sensory disorders of the shoulder, pain or prolonged chy-
lothorax. Those complications may occur in up to 80% of
post-surgery patients. It is a great number considering that
around 60% of patients are not found to have metastases to
the lymph nodes. For them, lymphadenectomy is of no ther-
apeutic but merely of a diagnostic value. Therefore, a method
has been sought for years to safely evaluate the lymphatic
system, while causing a limited number of consequences and
complications 16.
The application of sentinel lymph node biopsy (SLNB) in
BC was ﬁrst tested in the early 1990s. Numerous randomised
studies conﬁrmed its value and efﬁcacy in the evaluation of
axillary lymph node status. Researchers agree, however, that
full consequences of dropping ALND in patients with nega-
tive SLNB may only be assessed after results of prospective
studies are known on large groups of patients with long-term
follow-up. At present, there are nine studies of that kind being
conducted in the world.16,5,17
Since the 1990s, when Giuliano18 proposed the use of
blue dye to identify the sentinel node, markers have mostly
been based on radiocolloids or, more  recently, on indocyanine
green.17–20
As in the case of breast conserving therapy, SLNB has been
found to have its indications and contraindications. Whenever
possible, axillary lymphadenectomy in BC patients should
be replaced with SNLB. That technique is also advisable in
patients with the regional lymph node status established as
N0. SNLB can be applied with lymph nodes which are palpa-
ble or visible by imaging if the clinician ﬁnds them to be clear
of cancer (small, soft). For that group of patients, however, a
ﬁne-needle lymph node biopsy is recommended before the
decision to perform SLNB is taken.
Excluded from SLNB are patients with metastases to
regional lymph nodes (clinical or cytology conﬁrmed) or with
distant metastases; patients who do not agree for the pro-
cedure or those who report allergy to colloidal markers or
methylene dye. Breast-feeding women are recommended to
stop feeding before the administration of the marker and not
to resume until 24 h thereafter.16 Another issue that has been
discussed recently in relation to SLNB is whether it should
be used in pregnant women, especially that women tend to
start their motherhood at an increasing older age.21 Due to
teratogenic properties of methylene blue being and poten-
tial anaphylactic activity of Lympahazurin,22,23 Tc99-m has
been proved to be safe in use and of very little effect to the
foetus.24,25The analysis of the lymph node collected by SLNB being
more  detailed as compared to ALND, a problem of clinical
evaluation of micro metastases appeared.26 In the NSABP B-
32 study, the impact of micro metastases on ﬁve-year survival
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ate was low, 94.6 versus 95.8%, thus warranting the possibility
or patients with micro metastases to be followed-up without
aving to undergo ALND.27
.  Nomograms
n issue of increasing concern is the absence of metastases
n the other axillary lymph nodes examined in the case of
etastatic sentinel node (SN). This applies to as many  as
0% of patients.28,29 In their meta-analysis Degnim et al.
dentiﬁed 5 factors associated with the increased incidence
f metastases in non-sentinel lymph nodes in the case of
etastatic SN.30 These include: metastasis to the sentinel
ymph node of over 2 mm,  cancer inﬁltrating beyond the
ode capsule, tumour size >2 cm,  more  than one metastatic
entinel node, invasion within lymphatic vessels.30 There-
ore, mathematical models have been developed to evaluate
he risk of metastases in non-sentinel lymph nodes in the
ase of a metastatic sentinel node. Van Zee et al. proposed
 model based on data from the Sloan Kattering Memorial
ancer Centre, New York.31 Currently, other nomograms  are
lso available, including the Cambridge nomogram and the
tanford nomogram.  Researchers from the MD Anderson Can-
er CenteR have proposed a nomogram regarding the risk of
etastases to non-sentinel nodes in patients treated with
eoadjuvant chemotherapy.32–34
The results of ACOSOG Z0011 trial published in 2011 proved
o be a real breakthrough.35 The study comprised stage I and
Ia cancer patients. Patients with metastatic sentinel node
ere randomised into the ALND or control group. The groups
ere found to show no difference in terms of local recurrence,
isease free survival or overall survival. It needs to be stressed,
owever, that patients participating in the study had received
onserving therapy and post-surgery radiation therapy also for
he armpit region. Results of other ongoing studies are now
waited for this type of treatment to be wider implemented
nto the clinical practice.
.  Breast  conserving  treatment  (BCT)  as  a
redominant  technique  in  breast  cancer
anagement
his type of treatment is reserved for all BC cases unless
ontraindicated. The BCT procedure consists of a breast
onserving procedure (alternatively quadrantectomy, lumpec-
omy or wide tumour excision), diagnostic and therapeutic
rocedure on the axillary lymph nodes (ALND, SLNB) and
djuvant post-surgery radiotherapy. By today’s standards,
adiotherapy is a prerequisite procedure following BCT.
Indications and contraindications for BCT have changed
ver the years. Currently, conserving procedures are applied
or BC cases staged T1N0M0, T1N1M0, T2N0M0, T2N1M0. In
urope, eligible patients are those with tumours of up to 3 cm,
n the USA, of up to 5 cm.  Obviously, the most important con-
ition is patient’s consent and the lack of contraindications
or such a procedure. The contradictions include multicentric
but not multifocal) cancer, earlier breast radiotherapy, inabil-
ty to perform a total tumour dissection, inability to achievetherapy 1 9 ( 2 0 1 4 ) 165–172 167
an acceptable cosmetic effect, lack of patient’s consent, con-
nective tissue disease.3–5,36–39
In West Europe and the USA, BCT has in recent years
replaced radical modiﬁed mastectomy as a preferred method
of treating early BC. This could be achieved owing to educa-
tion and a wide access to screening tests which have enabled
diagnosis of cancer at early stages. According to the data pre-
sented by Morrow et al. as many  as 75% of newly diagnosed BC
cases in the United States are qualiﬁed for conserving therapy.
The authors note, however, that large geographical differences
persist in their country both in terms of diagnosis and quali-
ﬁcation to BCT.40
With properly selected patients, long-term results of BCT
and mastectomy are comparable, as conﬁrmed by large ran-
domised studies, such as Milan I or NSABP B-06.41,42 Both
methods differ signiﬁcantly in the incidence of local recur-
rence. With correct qualiﬁcation to BCT, the risk of local
relapse is 1% at 1 year and 10% at 10 years.43 The recur-
rence risk factors following BCT may be divided into three
groups: those related to the patient, the tumour or the treat-
ment method. The most important patient-related factors
include young age (below 35–40 years) and genetic predispo-
sition, mainly BRCA1 and BRCA2 gene mutation. The main
tumour-related risk is linked with the size of resection mar-
gins. The size of the tumour and lymph node involvement
are not prognostic factors for local recurrence, but rather for
distant recurrence. The relevance of treatment methods for
local recurrence is mainly related to the size of surgical exci-
sion (lumpectomy or quadrantectomy), radiation boost to the
tumour bed and, ﬁnally, the implementation of appropriate
adjuvant therapy (hormonal therapy, chemotherapy, targeted
therapy).44
Importantly, signiﬁcant principles of surgery and radia-
tion therapy in BC treatment may be considered to be similar
and mutually complementary. Each of this techniques, when
applied alone, fails to control locally advanced disease or sub-
clinical foci. Limitation in the case of surgery is the extent of
tissue resection to guarantee appropriate local control – “this
considered, each patient should be proposed mastectomy”.
The consequence in the case of BCT, but also mastectomy
(higher stages of cancer) is the presence of local recurrences in
65–80% of cases in the region of the scar, that is on the bound-
ary of the tissue removed or resection margins.37,45–49 Things
look different with radiotherapy. Average radiation doses are
sufﬁcient to control sub-clinical foci. However, with larger
groups of cancer cells – primary tumour – much higher radi-
ation doses are needed to control the disease. For example,
even a small T1c tumour requires a 50% higher dose of radia-
tion than that applied in treatment of sub-clinical cancer foci.
It is too much for the surrounding healthy tissue which is
threatened to be damaged.48,36,37,50 As a consequence, cancer
recurrence is mostly found in the centre of the tumour bed,
where the most cancerous tissue was located. Combining the
above combined makes up the image  of a modern conserva-
tive treatment: a surgical excision of tumour with a narrow
margin of healthy tissue followed by radiotherapy which erad-
icates the remaining microscopic cancer foci. The maximum
loco-regional control of cancer can be achieved without com-
promising the cosmetic effect by surgery being too radical or
radiation doses too high.
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6.  Occult  breast  cancer
The recent decades have seen a rapid growth in the rate of
diagnosed early occult breast cancer. This has become possi-
ble owing to the implementation of even better equipment and
techniques in the area of breast imaging, but above all owing
to BC screening programmes. Occult, so-called sub-clinical BC,
is assumed to represent 30% of all diagnosed tumours.51 The
increasing detection of occult BC and the approval of BCT as a
primary therapeutic technique by that group of patients is the
reality that surgeons are faced with today. A key to success-
ful treatment of occult BC is a precise excision of the tumour
with a proper margin of healthy tissue ﬁrst of all to cure but
also to reduce the risk of re-operation or recurrence. Therefore,
reliable and easy-to-use methods are searched for to precisely
localise and remove occult breast tumours or lesions highly
suspicious to be malignant, with concurrent SLNB.
The point is to excise the tumour with a proper margin of
healthy tissue within one surgical procedure. It is of partic-
ular importance as patients after total cancer resection with
clear margins during the ﬁrst procedure are at a lower risk
of recurrence compared to those who  need to be re-operated
due to insufﬁcient radicality of the ﬁrst excision.52 For that
reason, it is vital in the case of occult tumours to use available
localisation methods before and after surgery.
Needle localisation remains to be the most popular local-
isation method, ﬁrst described by Dodd in 1966. It involves
one or two straight or crooked wires inserted into the lesion
or right next to it with ends protruding above the surface of
the skin. The procedure is guided by stereotactic mammog-
raphy (most often), ultrasonography or MRI, with or without
local anaesthesia. During surgery, following the direction
of the wire  inserted into the breast, the lesion is localised
and excised, and then a radiogram of the specimen is per-
formed for control.53 This method allows to excise occult
breast tumours with accuracy of nearly 100%, however, 55–83%
patients require re-operation with margins being invaded by
cancer.54,55
In the late 1990s a new method of radiooccult lesion
localisation was introduced. It involves a pre-operative admin-
istration of radiopharmaceutic (99 m Technet on a protein
carrier) in the form of ultrasonography- or stereotactic MMR-
guided injection. A marker thus administered remains in
the tumour until surgery. During the operation, occult can-
cer lesions are easily localised and excised using a manual
gamma  probe. If early BC is diagnosed pre-operatively, a sec-
ond radiopharmaceutic is usually given in order to localise the
sentinel node. A simultaneous application of both methods in
one patients is referred to as SNOLL (sentinel node and occult
lesion localisation). An increasing number of comparative
studies indicate the advantage of that method over the ones
used before,51,56 ﬁrst of all due to its 100% efﬁcacy in the exci-
sion of occult tumours and a high rate of radical excisions.57
7.  New  therapeutic  options  in  neoadjuvant
therapy
Neoadjuvant (otherwise known as pre-operative or induc-
tive) systemic therapy (NST) was ﬁrst introduced in theiotherapy 1 9 ( 2 0 1 4 ) 165–172
1970s to manage advanced inoperable BC. A good clinical
response to this type of treatment made it possible to operate
patients previously disqualiﬁed from surgery. Currently, the
concept of NST embraces not only a standard pre-operative
chemotherapy, but also pre-operative hormonal and targeted
therapies. A breakthrough in this regard came with the publi-
cation of the results of two multi-centre randomised studies:
NSABP B-18 and EORTC 10902, which conﬁrmed the equiva-
lent value of neoadjuvant and adjuvant treatment in terms
of recurrence-free time and total survival. Furthermore, those
studies demonstrated that NST delivers an additional ben-
eﬁt of increased rate of conserving treatments and, more
importantly, acceptable incidence of local recurrence.58,59 The
main objective behind the use of NST is to control a potential
spread of the disease (cancer cells circulating in the peripheral
blood), reduce the weight of the tumour (complete patho-
logic response as an optimum) and, recently, enable BCT. NST
also allows an in vivo evaluation of response to the selected
pre-operative treatment regimen. This treatment modality is
believed to have a drawback of delayed local treatment which
may theoretically lead to the spread of primary cancer or
disease progressing to a more  advanced stage. Additionally,
NST may cause the patient to become resistant to the drugs
applied or more  exposed to the risk of post-surgery or post-
radiotherapy complications.60
Despite those limitations, patients with primarily operative
BC who wish to have their breasts preserved are increas-
ingly subjected to this method of treatment. If, initially, breast
tumour is found to be too large to enable BCT, NST seems to
be a natural therapeutic alternative. In the case when neoad-
juvant therapy reduces the size of tumour, patients initially
qualiﬁed for mastectomy may have their breasts preserved.
Numerous publications show that the proportion of patients
subjected to NST following BCT ranges from 13 to 83%. The
wide spread of results is caused by different inclusion and
qualiﬁcation criteria applied in particular clinical trials.61,62
Breast conserving therapy after neoadjuvant treatment is
challenging for the surgeon, as resection borders are more
difﬁcult to set with tumour being smaller in volume or even
disappeared. Therefore, each patient preliminarily qualiﬁed
for BCT should take necessary tests and procedures allowing
a precise localisation of the tumour before NST is started. The
safety of breast conserving therapy in terms of local recur-
rence in patients with initially large tumour remains to be a
matter of controversy. A high rate of local recurrence in reports
presented applies mostly to young women <40 years,63 who
are most determined to preserve their breasts. It is obvious
that treatment results depend strongly on a right qualiﬁcation
of patients for NST.
ALND remains to be a standard procedure in patients after
neoadjuvant therapy. Data show that in 25% of patients NST
destroys metastases in the armpit, meaning that ALND is
performed unnecessarily in those cases. Can SLNB be used
then to identify patients who do not need to be treated with a
mutilating axillary lymphadenectomy? This remains a matter
of dispute, particularly with respect to the optimal time of
SLNB. Supporters of SLNB before neoadjuvant treatment
believe the state of lymph nodes to be the most reliable at
that particular time (evaluation at diagnosis), thus permitting
to assess the stage of the disease and have an impact on the
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hoice of treatment (including drug regimens in chemother-
py or extent of radiotherapy ﬁelds). They also stress that
ST may change the anatomical course of lymphatic tracts
n the armpit. Then, SLNB performed after NST, may lead to
 lower rate of sentinel node identiﬁcation and higher rate of
alsely negative results.64,65
On the other hand, numerous studies conﬁrm that patients
ith initially clinically negative axillary lymph nodes beneﬁt
ore when sentinel node biopsy is made after neoadjuvant
reatment, resulting in conservation of axillary lymph nodes
n around 20–30% of patients.66
Concluding, NST, apart from its traditional role in treat-
ent of advanced breast cancer and inﬂammatory cancer, has
n the recent decade become one of therapeutic options in
reatment of early BC. However, many  questions concerning
his treatment modality are yet to be answered. It seems that
he multicentre studies being currently in progress will soon
llow to precisely deﬁne an optimal neoadjuvant treatment
nd select patients who can beneﬁt the most from it.
.  Intraoperative  radiation  therapy  (IORT)  –
ew  possibilities  in  BCT
or a long time the development of IORT techniques has
een restricted by logistic issues (transport from the operation
heatre to the radiotherapy department), unacceptable prolon-
ation in the time of surgery and a substantial growth in the
umber of massive inﬂammations of the operated site. It was
nly in the mid  1990s that a prototype of a mobile linear accel-
rator was proposed to spur the progress of IORT as we  know
t today. Machines produced nowadays can be moved between
urgery wards and easily docked to an operation table without
equiring any structural modiﬁcations in the rooms. They also
nsure an adequate level of radiation protection.67,68 There
re three mobile machines for intraoperative radiation ther-
py currently available in the world. These are: Intrabeam by
arl Zeiss (Oberkochen, Germany), Mobetron by IntraOpMed-
cal Inc. (Santa Clara, USA) and Novac-11 by Hitesys (Latina,
taly). Intrabeam works with a low photon energy (30–50 KVp),
he other two are linear accelerators producing electron beams
hence the term IOERT – Intraoperative Electron Radiotherapy).
t present, there are six intraoperative radiotherapy machines
perating in Poland.67
What does IORT change in terms of patient’s access to
CT? Many  publications report that the proportion of world’s
omen with BC qualifying for BCT and treated with that
ethod ranges from 10% to 80%, still a far cry from 100% level.
esides, as it turns out, 15–30% of patients who underwent
umpectomy for cancer do not receive post-surgery radiothe-
apy. Why then data are so poor? This results in part from
he duration of radiotherapy which, as mentioned before, is
–7 weeks and, as such, causes problems of convenience,
ccess and cost. Actual logistic limitations often relate to such
ssues as distance from the place of residence to the radiothe-
apy department, limited means of transport, lack of sufﬁcient
ocial support, lower status of ambulatory patients. For those
easons, many  patients chose to have their breasts removed
s a basic surgical procedure.48 Another problem that contin-
es to be discussed even in developed countries is the facttherapy 1 9 ( 2 0 1 4 ) 165–172 169
that women treated with breast conserving techniques rep-
resent up to 30% of radiotherapy department patients, thus
restricting a wider access to radiotherapy for other groups of
patients. For example, in Spain there were just 177 teleradio-
therapy machines in 2004, whereas the needs of that country
are at the level of 266–316.48 All the above considered, it needs
to be said that IORT may considerably improve BC patients’
access to BCT.
Here are the main clinical beneﬁts of using IORT:
– irradiation of cancer cells (sub-clinical cancer foci) before
they become capable of further proliferation,
– owing to better blood and oxygen supply to the intra-
operatively irradiated tissue, it becomes more  sensitive to
treatment (oxygenation effect),
– owing to a direct visualisation of the operated site, the
above-mentioned problem of “geographical loss” is avoided,
irradiation is ﬁt exactly within the surgical margins,
– part of radiotherapy side effects are avoided as the radiation
ﬁeld is surrounded by subcutaneous tissue and skin, and
dose to the heart and lungs is largely reduced,
– the compromise related to a possible delay in chemotherapy
is eliminated,
–  treatment costs are reduced and radiotherapy patient wait-
ing list shortened.67–69
Before oncology results for IORT in BCT are evaluated, a
note should be taken of the results obtained in a classical
procedure. It constitutes the basis for a proper comparison.
Approximately 5% of patients will have cancer recurrence
within ﬁve years following the end of treatment for invasive
breast cancer with BCT. The group will grow to 10% within
the ten-year follow-up. 85–90% of recurrences are located
directly in the tumour bed (true recurrence). Over six years
after treatment patients are observed to show an increased
incidence of cancer in other parts of the breast. Such cases are
believed to be new primary foci rather than recurrence of the
disease.36,69,70 Analysis of the literature and oncology results
in BCT shows that the lowest rates of recurrence are follows:
Age > 50 years; 0.4% annually (START B), 0.7% (Bartelink).
Age 41–50 years; 0.72% annually (Whelan), 1.2% (Bartelink).
Age 35–40 years; 0.72% annually (Whelan), 2.0% (Bartelink)
45,71,72.
It is the above results that intraoperative radiotherapy
results should be compared to.
Merrick in 1997 and Sedlmayer and Reitsamer in 1998 were
the ﬁrst to introduce an innovative technique of intraoperative
boost application. A single dose of 10 Gy was delivered by an
electron beam from a linac machine during a surgical breast
conserving procedure. Owing to that procedure, the period of
post-surgery radiotherapy was shortened by 1–2 weeks.73 In
2004, Reitsamer published results for a group of 190 women
treated in the above manner. A control group, who  received
classical treatment, consisted of 188 patients. No local recurr-
ences were found in the study group versus 4.3% in the control
group. What is important, the study group had a higher rate of
large intraductal component, which is a recognised negative
predictor.74 Another interesting report came from researchers
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of the International Society Intraoperative Radiation Therapy
(ISIORT). It presented results from six centres applying intra-
operative electron boost in BC treatment. The study group
consisted of 1131 patients. Local recurrence was found in 0.6%
of patients within a mean follow-up of 52.3 months.75 Another
study with a follow-up of 71.53 reported a recurrence rate of
0.2%.76 In his publication, Murawa  reported no local recur-
rence in a group of 118 patients treated with electron boost
with a follow-up of 22.81 months.67 The above reports and
the position of ISIORT deﬁne intraoperative electron boost fol-
lowed by whole breast post-surgery radiotherapy as the best
currently available golden standard in BCT.
The literature provides much more  information on the
competitive Intrabeam kilo-voltage system, such type of
machines being much more  numerous than mobile linear
accelerator systems. Intrabeam is much cheaper and has
provides the beneﬁt of high actual mobility. However, its radio-
biological value is quite often criticised. Dose delivered is
observed to fall considerably already at 1 cm from the appli-
cator surface. In Wenz’s report from the Mannheim centre,
197 patients were treated with photon boost by means of
Intrabeam at dose of 20 Gy on the applicator surface. Local
recurrence was found in 6 patients within a follow-up of 37
months.77,78 Vaidya and Baum reported results for a group
of 299 patients with a mean follow-up of 60.5 months. Local
recurrence was found in just 1.73% of patients at 5 years.79
Clearly then IORT boost delivers much better results than clas-
sical BCT procedure.
An active discussion is now being carried on about the
application of IORT not as a boost but a stand-alone radiation
technique following a surgical excision of BC under the BCT
procedure. This approach is referred to in literature as APBI
(Accelerated Partial Breast Irradiation). There are two clinical
studies being conducted in the world to analyse IORT tech-
niques in APBI. The ﬁrst one is the TARGIT-A study using an
Intrabeam machine. In 2010, the ﬁrst report was published
concerning 996 patients treated with that technique. The con-
trol group comprised 1119 patients treated managed with
a classical BCT. The mean follow-up was 24.6 months. The
local recurrence rate in 4 years was 1.2% in the study group
and 0.95% in the control group.80 The other study is ELIOT
which is being performed in the Milan Institute of Oncol-
ogy using a mobile linear accelerator. A total of 1822 were
treated with the APBI technique with a mean follow-up of 36
months. Local recurrence was found in 3.6% of patients at 3
years.81 When comparing the two above studies in her pub-
lication, Sautter-Bihl ﬁrst of all noted the difference in the
patient selection criteria. The ELIOT study included a much
larger group of patients with G3 cancers and metastatic lymph
nodes. Further, she strongly criticises the APBI technique indi-
cating numerous deﬁciencies of both series, particularly the
TARGIT.82 One thing is certain, follow-up periods in both stud-
ies are too short to be able to appraise the value of APBI, as
many local recurrences occur between 5 and 10 years after
treatment. Nonetheless, in the wake of the above studies and
similar ones employing brachytherapy techniques, recom-
mendations of the American Society for Radiation Oncology
and Groupe Europeen de Curietherapie – European Society
for Therapeutic Radiology and Oncology were issued in 2010
regarding the application of APBI in breast cancer patientsiotherapy 1 9 ( 2 0 1 4 ) 165–172
with favourable carcinogenic factors outside the clinical trial
regimen. Those guidelines are, however, criticised as being
premature by many  researchers including: the German Soci-
ety for Radiation Oncology and the National Comprehensive
Cancer Network.81,82
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